A variety of target antigens, including B-cell maturation antigen (BCMA), CD19, CD38, CD44v6, CD138, G protein‐coupled receptor, class C, group 5, member D (GPRC5D), immunoglobulin kappa light chain (IKLC), Fc receptor-homologue 5 (FcRH5), signaling lymphocyte activation molecule member 7 (SLAMF7), integrin β7 and natural killer group 2 member D (NKG2D), were investigated for the treatment of MM (Figure 3). Here, SDC1 is linked to Miyoshi myopathy.